Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15212509 | 0.91 | SYK (0.47) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL16408462 | 0.90 | SYK (0.46) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL15220113 | 0.81 | SYK (0.43) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL15212505 | 0.80 | SYK (0.46) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL15212398 | 0.78 | SYK (0.51) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL15220218 | 0.77 | SYK (0.46) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL2103987 | 0.76 | TRPV1 (0.51) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL655687 | 0.74 | SYK (0.64) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL15212360 | 0.72 | SYK (0.49) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL15212485 | 0.72 | SYK (0.53) | SYKJAK2EGFRLCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817306-B1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| EP-2817306-B1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-9073944-B2 | Cyclic diaminopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073944-B2 | Cyclic diaminopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20150025066-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025066-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| EP-2817306-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013126132-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013126132-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025066-A1 | CYCLIC DIAMINOPYRIMIDINE DERIVATIVES | SYK, BTK, LYN | SYK 1/4885JAK2 8/4885EGFR 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.